EP
INMB icon

Essential Partners’s INmune Bio INMB Stock Holding History

Essential Partners’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45K Sell
892
-1,279
-59% -$1.77K ﹤0.01% 2095
2026
Q1 		$2.45K Buy
2,171
+2,162
+24,022% +$3.08K ﹤0.01% 1917
2025
Q4 		$14 Buy
+9
New +$16 ﹤0.01% 2737

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Essential Partners's INMB Position: Q2 2026 in Review

Essential Partners reduced its INmune Bio (INMB) stake by 59% in Q2 2026, selling an estimated $1.77K and leaving 892 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #2095.

Essential Partners first reported a position in INMB in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.45K in Q1 2026. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Essential Partners held 892 shares of INmune Bio worth $1.45K as of Q2 2026.
  • Essential Partners sold 1,279 INmune Bio shares in Q2 2026, an estimated $1.77K.
  • INmune Bio made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2095 holding.
  • Essential Partners first reported a position in INmune Bio in Q4 2025 and has held it in 3 quarters since.
  • Essential Partners's INmune Bio position peaked at $2.45K in Q1 2026.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.